Results of a recently published study, “A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA®) and generic novo-methylphenidate ER-C (NOVO-generic)” confirms concerns expressed to CADDAC over the past number of years
Read more
Some researchers around the world have been thinking about a different way to think about mental and neurological disorders. They have found that current diagnostic categories may not align with new genetic and neuroscience findings. A unique Ontario p
Read more
I was just interviewed about a recent study published in the Journal of Pediatrics. This study looked at data from 378,881 children, ages 4-17, from 1997 to 2011 in Taiwan and analyzed the percentage of children who were diagnosed with ADHD and prescri
Read more
CADDAC's past year proved very successful.The highlights being; extensive advocacy work in British Columbia, Ontario and Manitoba; this years conference held in Ontario; the launch of our PREP two day parenting program; additional full day workshops in
Read more
The title says it all. Access this great blog post in the Huffington Post by Dr. Diane McIntosh, psychiatrist and assistant clinical professor at the University of British Columbia Here.
Read more
At the beginning of March CADDAC received a reply letter from Health Canada.View this letter Here.The letter reiterated what we have been told previously.Health Canada requires official reporting of a decrease in effectiveness of a generic when compare
Read more